Diabetes mellitus often develops in patients with hypertension. We investigated predictors of diabetes mellitus development in hypertensives at risk of developing the disease in the VALUE trial population. Among the 9995 non-diabetic hypertensive patients at baseline, 1298 patients developed diabetes mellitus during the average follow-up of 4.2 years. New-onset diabetes mellitus was defined from adverse event reports, information about new antidiabetic medication and/or a fasting glucose X7.0 mmol l À1 at the end of trial. Twentyfive potential baseline predictors of new-onset diabetes mellitus were analysed by univariate logistic regression and 14 of 25 predictors were found to be statistically significant with a P-value o0.05. The predictors were in order of decreasing significance; glucose, body mass index (BMI), age, uric acid, non-Caucasian race, haemoglobin, heart rate, randomized study treatment, history of coronary heart disease (CHD), gender, total cholesterol, proteinuria, potassium and creatinine. Multivariate stepwise logistic regression analyses were used and potential baseline predictors of new-onset diabetes mellitus were considered significant by four different models (P-value o0.001). The final multivariate model selected included all patients, but not treatment group as a potential predictor, and the six significant predictors identified from this model were glucose, BMI, non-Caucasian race, age, heart rate and history of CHD. In conclusion, glucose and BMI were the most important predictors of new-onset diabetes mellitus in hypertensive patients at high cardiovascular risk, and easily accessible clinical characteristics strongly predict patients at risk of developing diabetes mellitus.
Introduction
Diabetes mellitus is emerging as a health problem of epidemic proportions. Hypertension and diabetes mellitus often cluster together, 1 and recognizing risk factors or predictors of diabetes mellitus in high-risk populations would be important from a preventive point of view. Early detection and treatment of risk factors may decrease the chance of developing diabetes mellitus and diabetes complications. It is better to detect and to treat diabetes mellitus in its early stages than to treat serious complications and organ damage such as nephropathy, retinopathy and cardiovascular diseases. Predictors of diabetes mellitus in hypertensive patients have been evaluated in previous hypertension trials such as the Losartan Intervention For End point reduction in hypertension study (LIFE) 2 and the Captopril Prevention Project (CAPPP) 3 studies. In the LIFE study, 2 all patients had left ventricular hypertrophy and the CAPPP study comprised rather low-risk patients in Sweden and Finland. 3 We aimed to evaluate the predictors of new-onset diabetes mellitus in high-risk hypertensive patients enrolled in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, that is, a much broader hypertensive population than investigated in the LIFE and CAPPP studies. In the VALUE trial more than 15 000 hypertensive patients with various qualifying risk factors from more than 30 countries were included giving a widely representative and statistically powerful database to investigate potential predictors of diabetes mellitus in hypertensive patients.
Materials and methods

Study design
The VALUE trial was designed to compare cardiac outcomes between the angiotensin II-receptor blocker valsartan and the calcium channel blocker amlodipine in a population of hypertensive patients at high risk of cardiac disease recruited by a specific predefined age-and risk factor-dependent algorithm. [4] [5] [6] It is an investigator-designed, prospective, multicentre, double-blinded, randomized, activecontrolled, parallel-group trial. The primary objective was, for the same level of achieved blood pressure, to compare the long-term effects on the incidence of cardiac morbidity and mortality between antihypertensive treatment with valsartan and amlodipine. The trial was end point driven and the patients were followed for 4-6 years with regular visits, and upward-titration of medication was implemented in five steps to reach a goal blood pressure below 140/90 mm Hg. These present analyses were prespecified, but performed retrospectively and after the trial had been completed, due to the nature of the analyses. The study was approved by all concerned Ethics Committees and conducted in accordance with the Declaration of Helsinki. All patients gave written, informed consent. The study had an independent Data and Safety Monitoring Board.
Subjects
The VALUE trial included patients older than 50 years who were treated (92%) or untreated for essential hypertension at baseline. 5 Previously untreated patients were included if they had a mean sitting systolic blood pressure between 160 and 210 mm Hg (inclusive) and a mean sitting diastolic blood pressure below 115 mm Hg, or a mean sitting diastolic blood pressure between 95 and 115 mm Hg (inclusive) and a mean sitting systolic blood pressure below 210 mm Hg. 4 Additional inclusion criteria were presence of predefined combinations of cardiovascular risk factors and/or diseases according to an algorithm based on age and gender and detailed elsewhere. 4 Study end points Diabetes mellitus was at baseline 5 defined by the 1985 WHO criteria (fasting plasma glucose X7.8 mmol l À1 on at least two separate occasions). 7 In 1999, during the course of the study, WHO changed the definition of diabetes mellitus to a fasting plasma glucose of X7.0 mmol l À1 and/or glucose X11.1 mmol l À1 2 h after oral intake of 75 g glucose in venous plasma or serum (X12.2 mmol l À1 if capillary full blood). 8 During the blinded phase of the trial, the working classification of new-onset diabetes mellitus was therefore redefined to adhere with the WHO 1999 criteria, 8 and this protocol was prespecified in a study newsletter. Consequently new-onset diabetes mellitus in this article is defined as fasting glucose of X7.0 mmol l À1 during the trial in patients without diabetes mellitus or with glucose o7.0 mmol l À1 at entry. The new definition increased the number of diabetics at entry by 427 and these patients are also excluded from the following analysis.
To detect only new-onset diabetes mellitus, all patients who were diagnosed as diabetics at entry, received antidiabetic agents or had abnormal glucose levels were excluded. To detect new-onset diabetes mellitus in the trial three different criteria were used, but patients could only be counted once. The criteria were as follows: 
Statistical analysis
Both univariate and multivariate logistic regression models were used to evaluate baseline demographic, risk and disease factors, baseline laboratory variables and previous antihypertensive medication that significantly predicted diabetes mellitus development. The reason the logistic regression was used, was due to missing exact dates for diagnosing new-onset diabetes mellitus in some patients in the VALUE trial. Twenty-five potential baseline predictors of new-onset diabetes mellitus were identified and are shown in Table 1 . Univariate logistic regression analyses were used and predictors were identified as significant if Po0.05. The results are presented as w 2 with P-values, and odds ratio with 95% confidence intervals. An odds ratio 41 indicates and increased risk of diabetes mellitus development, while an odds ratio o1.0 indicates reduced risk.
Multivariate stepwise logistic regression analyses were used to further define significant baseline predictors for diabetes mellitus development in four models: (1) including study therapy, (2) excluding study therapy, (3) patients treated with valsartan and (4) patients treated with amlodipine. All 25 predictors were included in the multivariate analyses for Model 1, and 24 were included in Model 2, 3 and 4 (without treatment as a predictor). Predictors were considered significant if Po0.001. A stricter P-value was used in the multivariate analyses than in the univariate analyses to get a simple model with the most important predictors of diabetes mellitus development. The results are presented as w 2 and odds ratio with 95% confidence intervals.
To provide additional validation of the results from the multivariate stepwise model building, the patients with new-onset diabetes mellitus and those without were randomly split in two; a learning sample of 40% (3999) and a validation sample of 60% (5996) of the patients. The model building using multivariate stepwise logistic regression was then repeated on the learning sample with a significance criterion of Po0.05 and the identified model was then checked on the validation sample with a criterion of Po0.05.
Results
A total of 15 245 patients from 31 countries were randomized in the VALUE trial and the results showed no difference between the two drug regimens in the primary composite end point rate of cardiac morbidity and mortality. 6, 9 Among these, 5250 patients had diabetes mellitus at baseline by the 1999 WHO criteria, 8 and the remaining 9995 non-diabetic patients were included in this study on development of new-onset diabetes mellitus. During the mean 4.2 years of study duration (median 4.5 years, interquartile range 4.1-4.9 years), 1298 of these initial non-diabetic patients developed diabetes mellitus. Overall, 764 patients with new-onset diabetes mellitus were recognized in reports of adverse events from the investigators, 542 patients due to information about use of oral antidiabetic drug or insulin in study reports, and 700 patients due to measurement of fasting glucose X7.0 mmol l À1 at study end. As patients could count only once, 123 patients were diagnosed with newonset diabetes mellitus based on all three criteria, 472 diagnosed based on two criteria and 703 diagnosed based on one of the criteria.
Predictors of new-onset diabetes mellitus
From the univariate logistic regression analyses, 14 of the 25 selected potential baseline predictors were identified as significant (Po0.05), and are shown by decreasing w 2 values in Table 2 . Increased glucose at baseline and body mass index (BMI) had by far the highest odds ratios, and according to Table 2 each unit increase in glucose of 1 mmol l À1 or increase of 10 BMI units (kg m À2 ) was associated with an increased odds ratio of approximately 2.2.
From the multivariate stepwise logistic regression analyses, significant predictors (Po0.001) were identified for each of the four models and are shown in Table 3 . All these significant predictors from multivariate analyses were also being identified as significant predictors from univariate analyses. Significant predictors of new-onset diabetes mellitus from the first model including all patients were in order of decreasing w 2 values; baseline glucose, BMI, non-Caucasian race, age, heart rate, study therapy and history of coronary heart disease Predictors of new-onset diabetes mellitus TA Aksnes et al (CHD) (all Po0.001). There were significant treatment-glucose and treatment-heart rate interactions. However in the second model, not including the randomized study treatment, strong predictors of new-onset diabetes mellitus did not differ from those in the first model and this suggests that the factors associated with development of diabetes mellitus are independent of the treatment group. In the third model with only valsartan-treated patients, significant variables were glucose, BMI, heart rate and race, whereas in the fourth model with only amlodipine-treated patients, significant variables were glucose, BMI, race and age. Glucose at baseline had by far the strongest impact, followed by BMI. In addition to baseline glucose level and BMI, non-Caucasian race is consistently being identified as a significant predictor in all four models. We also reran our models without age as a predictor for model 1 and 2 due to possible selection of the qualifying algorithm in the VALUE trial, but the results did not change much as shown in Table 3 . Model 2 was selected as the final model, as this model includes all patients and is more general by not including study therapy as a potential predictor, and therefore better to use in other settings as well. When splitting the data into a learning sample and a validation sample; baseline glucose, BMI, non-Caucasian race, heart rate, history of CHD, study treatment and age were identified as predictors in the learning sample and confirmed by the validation sample. Three predictors was identified in the learning sample, but not confirmed in the validation sample or included in the main model: uric acid, creatinine and previous use of a-blockers. All, but previous use of a-blockers, were significant predictors identified by univariate analyses (Table 2) . This validation provides additional reassurance that the identified predictors from the final model do not represent mere chance findings.
Discussion
We assessed predictors of new-onset diabetes mellitus in 9995 participants in the VALUE trial of highrisk hypertensives who did not have diabetes mellitus at the outset of the trial. As many as 1298 patients developed diabetes mellitus according to WHO 1999 criteria during the 4.2 years of average follow-up. A total of 14 of 25 potential baseline predictors of new-onset diabetes mellitus were found to be statistically significant in the univariate logistic regression analyses. The predictors were in order of decreasing significance; glucose, BMI, age, The step-wise w 2 P-value were all highly significant (stepwise criteria P-valueo0.001 applied).
uric acid, non-Caucasian race, haemoglobin, heart rate, randomized study treatment, history of CHD, gender, total cholesterol, proteinuria, potassium and creatinine. Glucose, BMI, non-Caucasian race, age, heart rate and history of CHD remained significant in a multivariate model, which did not include the allocated treatment. Glucose at baseline was by far the most important risk factor for new-onset diabetes mellitus in all analyses and models used in our study. Impaired fasting plasma glucose defined as fasting plasma glucose between 5.55 and 7.0 mmol l À1 10 is a known risk factor for diabetes mellitus, 11 but there is probably a continuum of increased risk from even lower levels of 'normal' fasting glucose. The results from the MELANY study showed that increased fasting glucose level, even within the normal range (o5.55 mmol l À1 ), constitute an independent risk factor for type 2 diabetes mellitus. 12 These results may suggest that there is a relative overproduction of hepatic glucose already existent in patients at risk of developing diabetes mellitus.
Body mass index was beside baseline glucose, the next most important predictor of new-onset diabetes mellitus in the VALUE population. Obesity and fat distribution are well-known risk factors for type 2 diabetes mellitus. The natural history of diabetes mellitus development may be exaggerated by obesity because elevated levels of free fatty acids may both directly impair peripheral glucose utilization and accelerate the rate of hepatic gluconeogenesis, 13 as well as indirectly affect hepatic autoregulation through hypothalamic sensing.
14 Obesity-associated altered secretion of adipokines from adipocytes, macrophages in fat tissue, or both, have been suggested as other mechanisms being involved in mediating such dysregulation between fatty tissue and the liver. Some data have shown that waist circumference predicts diabetes mellitus marginally better than BMI. 15, 16 However BMI, and not waist circumference was measured in our study, and BMI was a highly significant predictor of new-onset diabetes mellitus in both univariate and multivariate analyses.
The risk of developing diabetes mellitus is increasing with age, but in our population increasing age at baseline was associated with a lower risk of developing diabetes mellitus during the trial period. We assume that this is caused by selection and the inclusion criteria inasmuch as only highrisk hypertensive patients above the age of 50 years could qualify for the study, that is, high-risk elderly hypertensives may, by being survivors of longstanding hypertension without diabetes mellitus development, gradually lose the metabolic ability of the disease, and these elderly hypertensives may survive because they do not have the same underlying risk of metabolic disease than the younger patients. Partially, this was also seen in the LIFE study. 17 The elderly could also qualify with less risk factors, but this is probably not the only explanation, as male gender was associated with a small, and expected, increased risk of diabetes mellitus in the univariate analysis in our study, and men could qualify with less risk factors than women. We also reran our model without age as a predictor, but the results did not differ much from the original model and we therefore decided to keep age as a predictor in our final model.
There are known differences in diabetic risk between races, and African-Americans are known to have an elevated risk of diabetes mellitus compared with whites or Caucasian. 18, 19 In our trial most of the patients were Caucasian (91.1%), and patients who were non-Caucasian (3.2% black, 3.4% oriental, 2.3% other races) developed more diabetes mellitus, and race was a significant predictor of new-onset diabetes mellitus in all analyses in our population.
Potassium at baseline was a weak predictor in the univariate model and did not contribute significantly to the multivariate logistic regression model. Hypokalaemia is a known potential mechanism for diabetes mellitus development, as hypokalaemia may blunt the release of insulin from the pancreas as originally proposed by Conn 20 to explain the apparent diabetic state found in primary aldosteronism. Uric acid and haemoglobin were also significant predictors in the univariate analyses for developing diabetes mellitus, but not in the multivariate models.
Baseline heart rate was a significant predictor of new-onset diabetes mellitus in all analyses except the multivariate analysis in model 4 (patients treated with amlodipine). An influence of sympathetic drive as an underlying pathophysiological mechanism 21 is suggested by the positive association between heart rate at baseline and new-onset diabetes mellitus observed in both treatment arms and which was statistically significant in the valsartan group. The known increased sympathetic effect of amlodipine, 22 that is, treatment-heart rate interaction may contribute to the diminished effect of heart rate as a predictor in the patients treated with amlodipine (model 4).
Diabetes mellitus was detected in 1298 subjects of the 9995 at baseline non-diabetic subjects, and a significant difference in favour of less diabetes mellitus in the group treated with valsartan was seen regardless of criteria used to define diabetes mellitus. 23 Study treatment was a highly significant predictor of new-onset diabetes mellitus and treatment with the angiotensin II-receptor blocker valsartan reduced new-onset diabetes mellitus by an absolute 3% and a relative 23% compared with amlodipine over the 4.2 year average length of the study. 6, 23 This translates into a NNT (number needed to treat) of 33 patients to prevent one case of new-onset diabetes mellitus. 23 The mechanism for the differential effects of the two vasodilating agents is, however, not firmly established.
A history of CHD was a significant predictor in both the univariate and multivariate model including all patients, but a previous history of cerebrovascular disease or peripheral arterial occlusive disease were not significant predictors in any of the analyses, possibly because of fewer patients included with these diseases compared to patients with CHD. Another reason may be differential relations between different risk factors and different cardiovascular diseases, that is, hypertension is more directly related to cerebrovascular and peripheral artery diseases.
In the LIFE study, a total of 562 patients of the 7998 non-diabetic hypertensive patients developed diabetes mellitus. 2, 24 The LIFE study was the first study that made use of the ability to analyse the appearance of new-onset diabetes mellitus in patients with different levels of risk, and significant predictors of new-onset diabetes mellitus from multivariate analyses were glucose (non-fasting), BMI, high-density lipoprotein-cholesterol, systolic blood pressure and history of previous use of antihypertensive drugs. 2 However, the LIFE study included fewer patients from fewer countries than the VALUE trial, and the study population was selected due to the presence of left ventricular hypertrophy in their echocardiograms. High-density lipoprotein-cholesterol was not studied as a predictor in the VALUE trial, and systolic blood pressure was not a significant predictor in our univariate analyses possibly due to the roll-over design of the study, which did not include a washout period without antihypertensive drugs 4 and thus the lack of true baseline blood pressures. 5 In the CAPPP study, glucose, BMI, haemoglobin, age, the interaction between systolic baseline blood pressure and newly diagnosed hypertension, cholesterol and previous antihypertensive treatment were all significant risk factors in a multivariate analysis. 3, 25 The CAPPP study included low-risk patients from Sweden and Finland indicating a less general population. Other known risk factors for diabetes mellitus development evaluated in, for example, West of Scotland Coronary Prevention Study such as high-sensitivity CRP, 26 triglycerides 27 and ALAT, 28 have not been evaluated in our population. There are also developed risk tests or risk scores, for example, the American and the Finnish Diabetes Associations, 29, 30 that emphasize on age, BMI, waist, glucose level, diet, physical activity and family history, to calculate a patients risk for diabetes mellitus development. Information about family history of diabetes mellitus and physical activity are not included in the VALUE database.
The VALUE trial included more than 15 000 hypertensive patients from more than 30 countries; however, this is still a high-risk population of mainly Caucasian individuals (91.1%), which also limits the possibility to generalize. Another limitation of the study is the age and gender algorithm that was used for recruitment, limits the precision of using these two variables as completely reliable predictors. Strengths of the study are the large data set, the tidy data collection with complete information on about 99% of participants including very few lost to follow-up 6 and the thorough scrutiny of two blinded databases, for adverse events and new drug treatment of diabetes mellitus, with fasting glucose added to capture all patients who developed diabetes mellitus. The investigators were urged to use the WHO 1999 definition of diabetes mellitus, 8 but these reports were not adjudicated and we cannot rule out some misclassification by the investigators. But by using three different databases, we were making the results more robust as the patient could qualify with one, two or three of the criteria, and could only count once in the final database. The multivariate model was also validated by fact that the results based on randomly selected learning and validation samples were highly consistent with the results based on the overall data set and this indicate robustness of our findings.
Large-scale randomized clinical trials are not designed to investigate pathophysiological issues and can only suggest possible mechanisms behind development of diabetes mellitus. Information about family history of diabetes mellitus and physical activity, diet, waist-hip-ratio, insulin, triglyceride and high-density lipoprotein-cholesterol level, all well-known risk factors for diabetes mellitus development, are not included in the database. On the other hand, the baseline predictors found in our study can easily be evaluated and used by physicians in treating patients in daily practice. It has been shown that screening for diabetes mellitus in general practice by measuring fasting blood glucose concentration is feasible, but has a very low yield in low risk population; 31 it could therefore be more beneficial in a high-risk patient group such as the present study population.
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